X
Saturday, May 10, 2025
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

    Continuous Bioprocessing Market to Surge by 2028

    Advancing Asia-Pacific Healthcare & Biopharma Innovation

    Generative AI in Pharma: Opportunities & Challenges

    Global Biopharma Market to Hit $566B by 2032

    AI Boosts Small Molecule Therapies for I&I Diseases

    Celonic Group Signs Long-Term Multi-Year Manufacturing Service Agreement with LINDIS Biotech for the Commercial Supply of Catumaxomab

    Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

    Continuous Bioprocessing Market to Surge by 2028

    Advancing Asia-Pacific Healthcare & Biopharma Innovation

    Generative AI in Pharma: Opportunities & Challenges

    Global Biopharma Market to Hit $566B by 2032

    AI Boosts Small Molecule Therapies for I&I Diseases

    Celonic Group Signs Long-Term Multi-Year Manufacturing Service Agreement with LINDIS Biotech for the Commercial Supply of Catumaxomab

    Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

ABU Dhabi launches Hope Consortium for global vaccine distribution

Content Team by Content Team
26th November 2020
in News, Packaging & Logistic
ABU Dhabi launches Hope Consortium for global vaccine distribution

Amid an anticipated surge in vaccine logistics demand, Abu Dhabi is poised to cement its position as the global logistics hub to facilitate COVID-19 vaccine distribution across the world, after spearheading the launch of the Hope Consortium.

Comprising leading Abu Dhabi and global entities, the Hope Consortium represents a complete supply chain solution to address vaccine transport, demand planning, sourcing, training, and digital technology infrastructure, and facilitate vaccine availability across the world.

The news follows Hope Consortium member Etihad Cargo and the consortium transporting five million vaccines in November on behalf of the Department of Health – Abu Dhabi, which is spearheading the consortium and will oversee regulatory compliance, full chain expertise and scientific insight. The consortium also includes Abu Dhabi Ports Group, Rafed, the healthcare purchasing arm of Abu Dhabi-based ADQ, and Switzerland’s award-winning SkyCell, which develops next-generation, temperature-controlled logistics containers for the pharmaceutical industry. As part of the Hope Consortium, SkyCell will establish a regional service and manufacturing centre in Abu Dhabi.

The Hope Consortium has pooled its collective expertise to garner a multi-faceted capability to provide logistics services to handle over six billion doses from the vaccines being developed and manufactured around the world – whether in single or multi doses – in cold and ultra-cold conditions in 2021, rising to over three times more doses by the end of next year – the largest capacity and logistics capability regionally and one of the largest globally.

“The Hope Consortium is a prime example of how Abu Dhabi is leading in providing solutions, capabilities and capacities to help the world get through this global pandemic. It is a continuation of all players’ collaboration of a UAE-based public-private partnership that spans the globe. While assuring vaccine supply to the domestic market, the Hope Consortium will offer international governments, non-governmental organisations, and vaccine suppliers a cohesive solution across every supply chain step – from air freight, regional storage and temperature monitoring, to inventory management, cold and ultra-cold container solution, regulatory clearance, and healthcare and pharma quality assurance,” explained HE Sheikh Abdullah bin Mohammed Al Hamed, Chairman, Department of Health – Abu Dhabi.

“Developing a vaccine is only the first step in getting to a solution, getting that vaccine to the whole globe, while maintaining a robust integrity of temperature is an equal challenge by itself, the Hope Consortium will provide that solution on the highest level of quality. Consortium partners already have extensive expertise in the global delivery of millions of COVID-19 related items, such as personal protective equipment, diagnostics consumables, vaccines and pharmaceuticals. As we progress talks with vaccine manufacturers to apprise them of our global distribution capabilities, the Hope Consortium will harness the united expertise of various Abu Dhabi and UAE stakeholders to provide a fully-fledged, end-to-end solution specifically for COVID vaccine distribution needs, he added.”
Distribution of the vaccines, which will be stored in Abu Dhabi Ports Company facilities, will be carried out by Etihad Cargo, the first Middle Eastern carrier to gain IATA’s Centre of Excellence for Independent Validators (CEIV) certification for pharmaceutical logistics. The UAE’s national carrier will leverage its extensive intercontinental network, fleet and charter flights to supply vaccines globally.

“With two thirds of the world’s human footprint within a four-hour flight of Abu Dhabi, the UAE capital’s investment in technological expertise and world-class infrastructure facilities means we can serve as a global logistical hub to, and for, the world,” explained Tony Douglas, Group Chief Executive Officer, Etihad Aviation Group. “Etihad Cargo’s role in the consortium will leverage our outstanding pharmaceutical logistics expertise and specialised pharma and healthcare service, PharmaLife, the IATA CEIV Pharma certified product capable of facilitating temperature-sensitive cargo between +25?C and -80?C. Our network reach across key destinations will be supported by the utilisation of our charter operations to meet global demand for swift and secure COVID-19 vaccine shipments.

“We are already managing all anticipated shipment elements through our dedicated COVID-19 vaccines workforce,” Douglas added. “A dedicated pharmaceutical handling facility to accommodate increased capacity at our Abu Dhabi hub is also currently under review, as well as additional thermal covers and enhanced capabilities at origin stations based on established pharma trade lanes and specific requests.”

As part of the Hope Consortium, Abu Dhabi Ports, which has the Middle East’s largest capacities for cold chain and ultra-cold storage, will leverage its capabilities as an innovation epicentre serving the Middle East and wider world through Abu Dhabi as a supply chain gateway connecting East and West.

“This collaboration is in line with our ethos of creating innovative ideas, concepts, solutions and opportunities,” said Mohamed Juma Al Shamisi, Group CEO of Abu Dhabi Ports. “Abu Dhabi Ports plays a key role in supporting the Abu Dhabi vision in advancing logistic services in the emirate and leading the post-COVID-19 revival and economic recovery through robust partnerships. Our expansive operations at KIZAD are among the largest cold chain and ultra-cold storing in the region and enable us to support the emirate’s drive to spearhead global immunisation efforts that will positively impact millions of lives. In addition to leveraging our world-class trade facilitation expertise, our efforts also rest on our Maqta Gateway subsidiary, which is playing a leading role in the development of integrated, digital, global commerce,” informed Shamisi.

Dr Noura Al Dhaheri, Head of Digital Cluster – Abu Dhabi Ports, CEO of Maqta Gateway, said, “Supporting the uninterrupted flow of critical cargo, such as medical and food supplies have been crucial in Abu Dhabi Ports’ story during 2020, but the distribution of vaccines will form the most significant success to date. Maqta Gateway is committed towards creating innovative digital solutions to boost the transparency and integrity of the region’s supply chain.”

Rashed Al Qubaisi, Chief Executive Officer, Rafed, which has already managed large volume products before and during the pandemic for the UAE and humanitarian initiatives, added: “Our expertise in centralised procurement services will provide vital support to the consortium. Through our collaboration we will better consolidate our efforts for the benefit of our global partners in the public and healthcare sectors.”

The Hope Consortium intends to transport the vaccines using SkyCell’s hybrid containers. The storage and transportation containers are secured through an IoT monitoring service which tracks temperature conditions to ensure sensitive vaccines are protected even under extreme conditions. With efficient insulation and cutting-edge cooling technology, the containers maintain steady temperatures for an average of 202 hours (8.4 days) and self-recharge automatically in a cooling chamber or reefer truck.

“Our hybrid containers will safeguard the full efficacy of vaccines that are vital to defeat the pandemic, all while reducing long-term business and environmental costs,” explained Richard Ettl, Chief Executive Officer of SkyCell. “The Hope Consortium has the right partners, infrastructure and service ecosystem to ensure time and temperature sensitive transportation in a seamless cool chain operation.”

The consortium will also be looking to partner with players and stakeholders to improve its offering and innovative solution for the benefit of humanity.

Previous Post

Pfizer Doses First Participant in Phase 3 Study Evaluating anti-TFPI Investigational Therapy

Next Post

Phase-3 trial of Bharat Biotechs Covaxin commences in AIIMS

Related Posts

Clinical Trials

Bio-Rad to Acquire Stilla Technologies by Q3 2025

28th February 2025
News

Types of Pharmaceutical Waste and How to Dispose of Them

31st December 2024
Developing Pharma Skills With Life Sci For Growth Initiative
News

UK Medicine Manufacturing Regulatory Framework For Care

6th November 2024
News

Nanoemulsion Drug Delivery Enhances Tuberculosis Care

6th November 2024
News

The Future of Drug Delivery Systems In Modern Medicine

6th November 2024
Revolutionizing Drug Discovery With AI For A Greener Future
News

AI and Nanotech Innovations in Advancing Drug Discovery

5th November 2024
Next Post
Phase-3 trial of Bharat Biotechs Covaxin commences in AIIMS

Phase-3 trial of Bharat Biotechs Covaxin commences in AIIMS

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Notifications